

FOI 3162

26<sup>th</sup> June 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira - 6
- Adalimumab Biosimilar - 191
- Etrasimod - 0
- Filgotinib - 0
- Golimumab - 1
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 109
- Mirikizumab - 1
- Ozanimod - 0
- Risankizumab - 3
- Tofacitinib - 3
- Upadacitinib - 28
- Ustekinumab – Stelara - 12
- Ustekinumab Biosimilar - 91
- Vedolizumab - 113

**Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:**

- Adalimumab – Humira - 0
- Adalimumab Biosimilar - 64
- Etrasimod - 0
- Filgotinib - 0
- Golimumab - 1
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 61
- Mirikizumab - 1
- Ozanimod - 0

- **Risankizumab - 1**
- **Tofacitinib - 3**
- **Upadacitinib - 15**
- **Ustekinumab – Stelara - 6**
- **Ustekinumab Biosimilar - 28**
- **Vedolizumab - 58**

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)